Focused On-demand Library for tRNA-splicing endonuclease subunit Sen2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

tRNA-intron endonuclease Sen2

Alternative UPACC:

Q8NCE0; B7Z6K1; C9IZI7; G5E9Q3; Q8WTW7; Q9BPU7


The tRNA-splicing endonuclease subunit Sen2 plays a pivotal role in cellular function by ensuring the proper splicing of precursor tRNA, a critical step in the maturation of tRNA molecules necessary for protein synthesis. This enzyme, also known as tRNA-intron endonuclease Sen2, is integral to the tRNA-splicing endonuclease complex, facilitating the precise cleavage of pre-tRNA to release introns and form mature tRNA molecules. Its activity is essential for maintaining the fidelity of protein translation and overall cellular health.

Therapeutic significance:

Given its crucial role in tRNA splicing, mutations in the gene encoding tRNA-splicing endonuclease subunit Sen2 are linked to Pontocerebellar hypoplasia 2B, a severe neurological disorder. Understanding the role of tRNA-splicing endonuclease subunit Sen2 could open doors to potential therapeutic strategies for this debilitating condition, highlighting the importance of targeted research in uncovering novel treatment avenues.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.